Shopping Cart
- Remove All
Your shopping cart is currently empty
Quavonlimab (MK-1308) is a novel human monoclonal antibody designed to selectively target and block the immune checkpoint molecule cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), investigation of quavonlimab in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) has shown encouraging anti-tumor activity along with an acceptable safety profile,making it an interesting compound for the reasearches into advanced non-small cell lung cancer (NSCLC).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $332 | In Stock | |
| 5 mg | $996 | In Stock | |
| 10 mg | $1,570 | In Stock | |
| 25 mg | $2,330 | In Stock | |
| 50 mg | $3,130 | In Stock |
| Description | Quavonlimab (MK-1308) is a novel human monoclonal antibody designed to selectively target and block the immune checkpoint molecule cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), investigation of quavonlimab in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) has shown encouraging anti-tumor activity along with an acceptable safety profile,making it an interesting compound for the reasearches into advanced non-small cell lung cancer (NSCLC). |
| Synonyms | MK-1308, MK1308 |
| Cas No. | 2254059-25-9 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.